Quick Takeaways
- Loyal has secured $100M in Series C funding, led by age1 with participation from Baillie Gifford, bringing its total funding to over $250M.
- Its lead candidate, LOY-002, is a once-daily prescription pill designed to target the underlying metabolic mechanisms of aging in senior dogs. The program has already achieved Reasonable Expectation of Effectiveness (RXE) and Target Animal Safety (TAS), meeting 2 of 3 major requirements for US FDA Expanded Conditional Approval (XCA), while also completing enrollment in the STAY study, which is tracking 1,300 dogs across 70 clinics, the largest veterinary trial to date.
- If approved, LOY-002 could become the first FDA-approved drug to extend lifespan itself in any species, marking a major shift toward preventive, longevity-focused care in veterinary medicine. The new funding will support final regulatory submissions, team expansion, manufacturing scale-up, and commercial launch readiness.
Why It Matters?
Loyal’s raise reinforces longevity as a serious, institution-backed frontier in veterinary medicine, moving it from niche concept to an emerging preventive care category.
If LOY-002 secures conditional and then full approval, it could redefine standards of care for senior dogs, shifting spend toward long-term healthspan management and creating a new class of “aging-modifying” therapies.
The scale of the STAY trial and manufacturing build-out also signals that payers, clinics, and pet owners should prepare for a future where lifespan extension is discussed alongside vaccines, nutrition, and chronic disease management.
Source: Businesswire
